Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

Renal Impairment Clinical Trial

— CINOPSIS CT  

Official title:

A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Optiray 320 mgI/mL and Visipaque 320 mgI/mL on Renal Function in Subjects With Stable Reduced Renal Function Undergoing Contrast-enhanced Computed Tomography

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00793182
• Other study ID #: 1323-07-872
• Status: Terminated
• Phase: Phase 4
• Start date: January 2009
• Est. completion date: June 2009

Study information

• Verified date: February 2019
• Source: Guerbet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography.

Description:

Contrast-induced nephropathy (CIN) is an acute decline in renal function after the administration of iodinated contrast agents. CIN is commonly defined as an increase in post contrast serum creatinine (SCr) greater than or equal to 25% or an absolute increase greater than or equal to 0.5 mg/dL from pre contrast baseline values. Study will evaluate and compare the effects of two (2) contrast media products on renal function in subjects with stable reduced renal function while undergoing contrast-enhanced computed tomography.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and females 18 years of age or older

• Subjects scheduled for a clinically indicated CECT requiring 40 grams of iodine (125 mL)

• Subjects have an abnormal screening SCr that results in a calculated eGFR of < 60 mL/min/1.73 m2 using the MDRD formula and acute causes for an elevation in SCr have been excluded

• Subjects have stable reduced renal function which is defined as an abnormal screening SCr measurement with a < 15% difference from the oldest historical SCr measurement obtained within the proceeding 1 week to 12 weeks

• Subjects must provide written consent and agree to abide by the site and study requirements

Exclusion Criteria:

• Subjects previously entered into this study

• Subjects on dialysis

• Subjects received any investigational drug within 30 days of contrast administration or participated in an investigational study within 30 days prior to study enrollment

• Subjects have undergone a procedure using iodinated or gadolinium contrast agent within 7 days prior to contrast administration, or is scheduled to receive additional doses of contrast agents during the 48-72 hour post-study contrast administration

• Subjects in acute renal failure or have one or more known causes of acute renal failure

• Subjects have known or suspected unstable renal function

• Subjects scheduled for a surgical intervention or other procedure within 72 hours after the contrast administration

• Subjects taking NSAIDs (with the exception of ASA) and/or any type of diuretics who cannot discontinue these drugs post contrast administration and hold all subsequent doses until the 48-72 hour post contrast SCr has been drawn

• Subjects taking aminoglycosides

• Subjects known to have an organ transplantation

• Subjects have severe congestive heart failure (Class III-IV)

Related Conditions & MeSH terms

• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• Ioversol 320 mgI/mL
125 mL of Ioversol administered in the vein
• Iodixanol 320 mgI/mL
125 mL of Iodixanol administered in the vein

Locations

Country	Name	City	State
United States	Maine Research Associates	Auburn	Maine
United States	UAB Hospital	Birmingham	Alabama
United States	Geisinger Medical Center	Danville	Pennsylvania
United States	Genesys Regional Medical Center	Grand Blanc	Michigan
United States	Methodist Medical Center of Illinois	Peoria	Illinois
United States	Albert Einstein Medical Center	Philadelphia	Pennsylvania
United States	Temple University Hospital	Philadelphia	Pennsylvania
United States	Wake Research Associates	Raleigh	North Carolina
United States	University of Rochester Medical Center	Rochester	New York
United States	Radiology LTD	Tucson	Arizona
United States	Trinity Clinic	Tyler	Texas
United States	Providence Hospital	Washington	District of Columbia
United States	Radiology Consultants, Inc.	Youngstown	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Guerbet

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Patients With Contrast-induced Nephropathy (CIN)	Contrast-induced nephropathy (CIN) is defined as an increase of = 25% or an increase of = 0.5 mg/dL from baseline serum creatinine (SCr), within 48 - 72 hours after contrast medium administration.; For each patient, SCr values were measured from 2 to 24 hours before and from 48 to 72 hours after contrast medium administration.	Based on the SCr values of each patient measured from 2 to 24 hours before and from 48 to 72 hours after contrast medium administration